Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 311 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe MOST POPULAR Cancer Survivor with Strong Family History Was Denied Regular Screening Because... June 30, 2021 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... June 8, 2022 First immunotherapy approved for cervical cancer in England and Scotland May 16, 2023 Load more HOT NEWS From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror Atlantic rowing trio smash world record and raise thousands for cancer... New on NCI’s Websites for March 2022 FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as...
